英语助手母语润色网
查找母语润色产品
立即注册
下单注意事项

化疗方案比较翻译

发表时间:2018-11-23  浏览次数:86  
字体大小: 【小】 【中】 【大】

原文:

This author has personally seen responses with combinations of FolFOX (5-fluorouracil, leucovorin, and oxaliplatin), XELOX (capecitabine and oxaliplatin), and combinations with irinotecan and cetuximab. There has been some additional interesting hints of activity with combinations of capecitabine with gemcitabine, a combination initially developed for the treatment of renal cell cancer.21 Responders with capecitabine and gemcitabine more typically occur inpatients who responded to the Gem-FLP combination. Therefore, it is unlikely that this combination would overcome initial resistance to 5-fluorouracil–based therapy. Given the similarity with colonic cancer, this author would also recommend consideration of the addition of bevacizumab, and inhibitors of epidermal growth factor receptor (EGFR), including cetuximab, or panitumumab when available. This author also has seen cases in which patients may have benefited from long-term maintenance therapy with these antibodies. Additional responses have been reported with gemcitabine and cisplatin,  S-1/cisplatin, and irinotecan. Unfortunately, the small numbers of patients treated limits our ability to validate these findings.

 

译文:

作者亲历患者接受FolFOX 化疗方案(5-氟尿嘧啶+甲酰四氢叶酸+奥沙利铂)、XELOX(卡培他滨+奥沙利铂)或伊立替康联合西妥昔单抗化疗后,出现应答。此外,卡培他滨联合吉西他滨(最早用于治疗肾细胞癌)也可能会有一定的临床获益。多数情况下,对卡培他滨联合吉西他滨产生应答的患者也对Gem-FLP化疗方案产生应答。因此,很难确定该方案能克服基于5-氟尿嘧啶的治疗方案所存在的问题。鉴于与结肠癌存在一定相似性,作者还推荐可选用贝伐单抗、表皮生长因子受体(EGFR)抑制剂,如西妥昔单抗或帕尼单抗。再者,作者亲历有些患者接受针对这些抗体的长期维持治疗后,也有一定的临床获益。其他研究表明,吉西他滨+顺铂, S-1/顺铂,与伊立替康也有一定的临床获益。但是,这些研究患者数量较少,难以判定其疗效。


文章评论
发表评论:(匿名发表无需登录,已登录用户可直接发表。) 登录状态: 未登录,点击登录

地址:上海徐汇区田林东路55号汇阳广场20楼C23和C22室(英文论文润色服务) 热线电话:400-0871-070

旗下母公司:上海译境翻译服务有限公司   联系电话:021-6131 4984

                            英语助手英文论文润色官方网版权所有沪ICP备14046471号-1 © 2007-2027 E-ging All Rights Reserved.

                           咨询电话:137 6474 0063      咨询QQ:229632732          服务邮箱:info@e-ging.xyz